Monday, 27 June 2022


Dale Gordon Appointed CEO of Mirus Bio to Support GMP Expansion

15 December 2021 | News

Gamma Biosciences, a global life sciences company serving the academic and advanced therapy market, today announced the appointment of Dale Gordon as Chief Executive Officer (CEO) of its operating company Mirus Bio. Gordon succeeds founders Jon Wolff and Jim Hagstrom in carrying the scientific legacy of the company forward with an expanded focus on enabling both the research and biopharmaceutical manufacturing markets.

Image Source : Public Domain

Image Source : Public Domain

“We have been delivering transfection reagents to the research community for more than two decades and are now moving into biopharma with the introduction of TransIT-VirusGEN GMP transfection reagents, enhancers and kits earlier this year,” Jim Hagstrom, co-Founder and President of Mirus Bio commented. “This product line is transformative, offering users the ability to package and transfer vector DNA to suspension and adherent HEK 293 cell types for increased production of recombinant AAV and lentivirus, all while helping to minimize safety and regulatory risks. With Dale on board, I am confident that we can continue to build our portfolio from research to GMP with the right tools customers need to develop life-saving advanced therapies.”

 

Gordon brings more than three decades of global leadership experience in life sciences to the new role, most recently as CEO of Gemini Biosciences. Prior to Gemini, Gordon held commercial leadership roles at GE Life Sciences (now Cytiva) and Merck Millipore.

 

“When we look at the exponential potential within this market to help save or drastically improve patient lives, it is important to remember the responsibility suppliers like Mirus have to support innovation,” Dale Gordon, incoming CEO at Mirus Bio stated. “I am excited to lead the team in taking a next generation approach to product development and iterative partnering that enables our customers’ research and bringing quality therapeutics to market faster across the academic to commercial spectrum.”

 

“Mirus Bio has a strong scientific legacy and culture that we want to carefully preserve as we expand the business to serve the biopharmaceutical industry. Dale’s experience in both research and regulated markets and his deep knowledge of the sector make him the perfect leader to take the company into this next phase,” said Matt Gunnison, CEO of Gamma Biosciences.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account